Diets with increased EPA, DHA with or without decrease in linoleic acid reduced headaches but did not significantly improve QOL<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, July 1, 2021 (HealthDay News) — Interventions that increase dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with or without a decrease in linoleic acid, alter bioactive mediators that are implicated in migraine and reduce headaches, but they do not improve headache-related quality of life, according to a study published online June 30 in The BMJ<\/em>.<\/p>\n Christopher E. Ramsden, M.D., from the National Institute on Aging in Baltimore, and colleagues conducted a three-arm trial involving 182 participants with migraines on five to 20 days per month. Participants were randomly assigned to the H3 diet (increase EPA+DHA to 1.5 g\/day and maintain linoleic acid at around 7 percent of energy; 61 participants), the H3-L6 diet (increase EPA+DHA to 1.5 g\/day and decrease linoleic acid to \u00e2\u0089\u00a41.8 percent of energy; 61 participants), or control diet (maintain EPA+DHA at <150 mg\/day and linoleic acid at about 7 percent of energy; 60 participants).<\/p>\n Compared with the control diet, the researchers observed increases in circulating antinociceptive mediator 17-hydroxydocosahexaenoic acid with the H3-L6 and H3 diets. There were improvements seen in the test assessing headache impact on quality of life with both the H3-L6 and the H3 diets, but these were not statistically significant. The H3-L6 and H3 diets decreased total headache hours per day, moderate-to-severe headache hours per day, and headache days per month, compared with the control diet. The decrease in headache days per month was greater with the H3-L6 diet than the H3 diet.<\/p>\n “This study provides a biologically plausible demonstration that pain can be treated through targeted dietary alterations in humans,” the authors write. “Collective findings suggest causal mechanisms linking n-3 and n-6 fatty acids to nociception, and open the door to new approaches for managing chronic pain in humans.”<\/p>\n Abstract\/Full Text<\/a><\/p>\n